Quarterly Result21 May 2025, 06:12 pm
Mankind Pharma Reports 27% Revenue Growth in Q4FY25, Surpasses INR 10,000 Cr in Domestic Revenue for FY25
AI Summary
Mankind Pharma, India's fourth largest pharmaceutical company, has announced its financial results for the quarter and financial year ended 31st March 2025. The company's revenue grew by 27% in Q4FY25, with adjusted EBITDA margins at ~23%. The domestic revenue surpassed INR 10,000 Cr in FY25. The growth was led by continued outperformance in Chronic, strong growth in the Consumer segment, and BSV consolidation. The company has laid a strong foundation for long-term sustainable growth with four key pillars - steady base business, fast growing specialty chronic, high potential OTC business, and high entry barrier super specialty portfolio of BSV.
Key Highlights
- Revenue from Operations at INR 3,079 Cr, up by 27% YoY
- Domestic revenue at INR 2,544 Cr, up 18% YoY, Exports at INR 535 Cr, up 100% YoY
- Adjusted EBITDA margin of 23.1% down by 120 bps YoY and PAT margin of 13.9%
- Diluted EPS of INR 10.3 down by 12.5% YoY
- Revenue from Operations at INR 12,207 Cr, up by 19% YoY for FY25